
    
      Secondary objectives of this clinical trial :

        -  To evaluate the effect of COPD and/or OSAS on the systemic inflammation,
           insulin-resistance and oxydative stress, in comparison with non COPD non OSAS patients.

        -  To evaluate the effect of COPD and/or OSAS on the inflammation and oxydative stress of
           the adipose tissue, in comparison with non COPD non OSAS patients.

        -  To validate the STOP-BANG questionnaire in patients undergoing a cardiovascular surgery
    
  